The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-04 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
These excitations result in excited state absorption peaks located below the diagonal and cross peaks. In 2DNMR, two distinct techniques, COSY and NOESY, are frequently used. The cross peaks in the first are related to the scalar coupling, while in the latter they are related to the spin transfer between different nuclei. In nonlinear two-dimensional infrared spectroscopy, analogs have been drawn to these 2DNMR techniques. Nonlinear two-dimensional infrared spectroscopy with zero waiting time corresponds to COSY, and nonlinear two-dimensional infrared spectroscopy with finite waiting time allowing vibrational population transfer corresponds to NOESY. The COSY variant of nonlinear two-dimensional infrared spectroscopy has been used for determination of the secondary structure content of proteins.
A hot dog is a grilled, steamed, or boiled sausage served in the slit of a partially sliced bun. The term hot dog can also refer to the sausage itself. The sausage used is a wiener (Vienna sausage) or a frankfurter (Frankfurter Würstchen, also just called frank). The names of these sausages commonly refer to their assembled dish. Hot dog preparation and condiments vary worldwide. Common condiments include mustard, ketchup, relish, onions in tomato sauce, and cheese sauce. Other toppings include sauerkraut, jalapeños, chili, grated cheese, coleslaw, bacon and olives. Hot dog variants include the corn dog and pigs in a blanket. These types of sausages were culturally imported from Germany and became popular in the United States. It became a working-class street food in the U.S., sold at stands and carts. The hot dog has become closely associated with baseball and American culture. Although particularly connected with New York City and its cuisine, the hot dog eventually became ubiquitous throughout the US during the 20th century. Its preparation varies regionally in the country, emerging as an important part of other regional cuisines, including Chicago street cuisine.
Which plants have which types of defense? Which herbivores, specifically, are the plants defended against? What chemical structures and mechanisms of toxicity are involved in the compounds that provide defense? What are the potential medical uses of these compounds? These questions and others constitute an active area of research in modern botany, with important implications for understanding plant evolution and medical science. Below is an extensive, if incomplete, list of plants containing one or more poisonous parts that pose a serious risk of illness, injury, or death to humans or domestic animals. There is significant overlap between plants considered poisonous and those with psychotropic properties, some of which are toxic enough to present serious health risks at recreational doses. There is a distinction between plants that are poisonous because they naturally produce dangerous phytochemicals, and those that may become dangerous for other reasons, including but not limited to infection by bacterial, viral, or fungal parasites; the uptake of toxic compounds through contaminated soil or groundwater; and/or the ordinary processes of decay after the plant has died; this list deals exclusively with plants that produce phytochemicals. Many plants, such as peanuts, produce compounds that are only dangerous to people who have developed an allergic reaction to them, and with a few exceptions, those plants are not included here (see list of allergens instead).
== Multiple valves == Multiple check valves can be connected in series. For example, a double check valve is often used as a backflow prevention device to keep potentially contaminated water from siphoning back into municipal water supply lines. There are also double ball check valves in which there are two ball/seat combinations sequentially in the same body to ensure positive leak-tight shutoff when blocking reverse flow; and piston check valves, wafer check valves, and ball-and-cone check valves.
Sources: en.wikipedia.org
After the battle, there were other several clashes between militiamen and gang members. Throughout the 2010s there were several arrests and convictions against militiamen and drug traffickers involved in the massacres. The militias managed to conquer several territories under the control of the Comando Vermelho, although some of them later returned to the gang's control after being reconquered during clashes. In November 2010, another massacre occurred between the military police and the CV, resulting in the deaths of 41 people. On 1 February 2012, during a raid conducted by the Polícia Militar (PM), a "Caveirão" was destroyed by the Comando Vermelho in the favela of Jacarezinho, no injuries were reported. During the course of the massacre, the CV and the militias began recruiting child soldiers. On 19 November 2016, during an operation of the PM, a military police helicopter was shot down by Comando Vermelho in the favela of Cidade de Deus, in the crash four policemen died. On 9 February 2020, a prominent militia faction leader, Adriano Magalhães da Nóbrega, also known as "Capitão Adriano" or "Gordinho", was seriously injured in a police operation and later died in a hospital. On 15 October, in one of the deadliest operations against militias, the PM clash with a convoy of the militias killing 12 paramilitaries on Itaguaí, also a policeman was injured. In the Morro do Fubá favela, the residents were forced to pay a monthly fee of 50 brazilian reals as part of a protection racket.
=== ZonaZoo === Officially implemented in 2003, ZonaZoo is the official student section and student ticketing program for the University of Arizona Athletics. The ZonaZoo program is co-owned by the Associated Students of the University of Arizona (ASUA) and Arizona Athletics yet run by a team of individuals called the ZonaZoo Crew. In 2014, ESPN ranked ZonaZoo as the top student cheering section in the PAC 12 conference and in 2015, and in 2018, ZonaZoo received the Best Student Section of the Year award from the National Collegiate Student Section Association.
=== TCI-Concor Multimodal Solutions Private Limited === Transport Corporation of India Limited and Container Corporation of India joint venture, the company provides multimodal rail road logistics services by combining TCI’s road transport network with CONCOR’s rail infrastructure.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.